Core Points - The recent tax reform focuses on standardizing tax incentives, accelerating the adjustment of VAT policies across various industries [1] - The Ministry of Finance, the General Administration of Customs, and the State Taxation Administration have announced the cancellation or adjustment of several VAT incentives [1] Wind Power Industry - The VAT exemption policy for onshore wind power, which allowed a 50% immediate refund since July 1, 2015, will be abolished starting November 1, 2023 [2] - From November 1, 2025, to December 31, 2027, a similar 50% immediate refund policy will be retained for offshore wind power [2] - The decision reflects the maturity and competitiveness of onshore wind technology, while offshore wind still requires support due to higher costs and challenges [2] Nuclear Power Industry - The VAT policy that allowed a phased refund for nuclear power plants will be phased out for new projects approved after November 1, 2025 [3][4] - Existing nuclear power plants will continue to benefit from the previous VAT refund policies until their respective deadlines [4] - This change indicates that nuclear power is now expected to compete on equal tax terms with other energy sources [4] Financing Leasing Industry - The VAT refund policy for financing leasing businesses, which applied to tax burdens exceeding 3%, will be abolished on November 1, 2023 [5][6] Aircraft Maintenance and Other Industries - The VAT exemption for aircraft maintenance services, which allowed refunds for tax burdens exceeding 6%, will be canceled [7] - Other industries affected include diamond trading, new wall materials, and coalbed methane extraction, with various VAT incentives being removed [7][8] Overall Tax Policy Context - The cancellation of these tax incentives aligns with the broader goal of standardizing tax policies and increasing fiscal revenue amid economic challenges [8] - In the first three quarters of the year, the general public budget revenue was 163.876 billion yuan, a 0.5% increase year-on-year, while expenditures grew by 3.1% [9]

Core Points - The adjustment of tax incentives for certain industries, such as wind power generation, reflects the achievement of policy goals and the need for timely withdrawal of tax benefits [1][2] - The new policy maintains a 50% VAT refund for offshore wind power products from November 1, 2025, to December 31, 2027, indicating a targeted approach to support specific sectors [1][2] Group 1 - The adjustment aims to enhance the precision of tax policies by canceling VAT refunds for onshore wind power while retaining benefits for offshore wind power, addressing both economic development and cost factors [2] - The changes focus on specific industries, regions, and entities, promoting a fair tax environment and competition, which is essential for building a unified national market [2] - The adjustments are expected to improve the VAT system and support the upcoming implementation of the VAT law in 2026 [2]

Core Viewpoint - The acquisition of 55% stake in Shaanxi Ruisheng Biological Technology Co., Ltd. by Haili Biological has faced significant challenges, leading to a price adjustment from 9.35 billion to 5.36 billion yuan due to declining revenue and net profit caused by market competition and tightened tax policies [1][2][3] Group 1: Acquisition Details - Haili Biological announced a supplementary agreement to adjust the acquisition price of Ruisheng Biological's 55% stake from 9.35 billion yuan to 5.36 billion yuan, requiring the seller, Meilun Company, to return a price difference of 3.99 billion yuan [1][2] - The overall valuation of Ruisheng Biological was adjusted from 17 billion yuan to 9.74 billion yuan based on an asset assessment report as of June 30 [2] - The profit commitments for 2025 and 2026 were revised to 50 million yuan and 58 million yuan, respectively [1] Group 2: Performance Challenges - Ruisheng Biological's revenue and net profit have declined due to two main factors: increased competition in the market and the tightening of previously applicable tax incentives, which has led to a shift to a general taxation method with a 13% VAT rate [2][3] - The average price of Ruisheng Biological's oral product line dropped by 40% in Q2, despite a slight increase in market share of 6% to 7% [2] - The company has faced challenges in maintaining profitability due to significant price declines that cannot be offset by market share gains [2] Group 3: Strategic Shift - Haili Biological's acquisition of Ruisheng Biological is seen as a strategic move to enter the human health sector, transitioning from the animal health industry [1][3] - Ruisheng Biological specializes in regenerative medicine products, including oral bone repair materials and absorbable biological membranes [3][4] - The company has had recent success with the acceptance of registration applications for new medical devices aimed at jawbone defect repair [4]